Therapeutic drug monitoring (TDM) and model‐informed precision dosing (MIPD) have
evolved as important tools to inform rational dosing of antibiotics in individual patients with …

Tuberculosis (TB) is still the number one cause of death due to an infectious disease.
Pharmacokinetics and pharmacodynamics of anti-TB drugs are key in the optimization of TB …

The aim of this operational handbook is to provide practical guidance on the implementation
of the World Health Organization (WHO) policy recommendations on the prevention and …

In recent years, many studies on population pharmacokinetics of linezolid have been
conducted. This comprehensive review aimed to summarize population pharmacokinetic …

Tuberculous meningitis disproportionately affects young children. As the most devastating
form of tuberculosis, it is associated with unacceptably high rates of mortality and morbidity …

Rifampicin-resistant tuberculosis (RR-TB) involves treatment with many drugs that can
prolong the QT interval; this risk may increase when multiple QT-prolonging drugs are used …

The prolonged treatment duration for multidrug-resistant tuberculosis (MDR-TB) makes
linezolid dosing difficult because of adverse effects associated with long-term use. We …

Introduction Management of concomitant use of ART and TB drugs is difficult because of the
many drug–drug interactions (DDIs) between the medications. This systematic review …

Children affected by rifampicin-resistant tuberculosis (RR-TB; TB resistant to at least
rifampicin) are a neglected group. Each year an estimated 25,000–30,000 children develop …

The World Health Organization estimates that 10 million new cases of tuberculosis (TB)
occurred worldwide in 2017, of which 600,000 were rifampicin or multidrug-resistant …